Tandutinib
Alternative Names: CT53518; MLN 518; MLN0518Latest Information Update: 05 Nov 2023
Price :
$50 *
At a glance
- Originator Millennium Pharmaceuticals
- Developer Millennium
- Class Antineoplastics; Quinazolines; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; Platelet-derived growth factor receptor antagonists; Proto-oncogene protein c-kit inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glioblastoma
Most Recent Events
- 31 Jul 2012 Discontinued - Phase-II for Glioblastoma in USA (PO)
- 11 May 2012 Phase-II clinical trials in Glioblastoma in USA (PO)
- 16 Feb 2012 Phase-I clinical trials in Solid tumours in USA (PO)